HEALTHCARE PROVIDER INFORMATION: EVUSHELD

Indications:

The FDA has issued an EUA for EVUSHELD (tixagevimab co-packaged with cilgavimab),for the **pre-exposure prophylaxis** of COVID-19. EVUSHELD received FDA for EUA December 8, 2021.

Dosage and Administration:

The dosage of **EVUSHELD** is 300 mg of tixagevimab and 300 mg of cilgavimab **administered as two separate consecutive intramuscular injections.** *Administer the IM injections at different injection sites, preferably one in each of the gluteal muscles, one after the other. Clinically monitor individuals after injections and observe for at least 1 hour.

Eligibility:

- 12 years of age and older weighing at least 40 kilograms (about 88 pounds)
- Not currently infected with the **SARS-CoV-2** virus and not recently exposed to an individual infected with **SARS-CoV-2**, **AND**
- Moderate to severely compromised immune systems due to a medical condition or taking immunosuppressive medications and may not mount an adequate immune response to **COVID-19 vaccination**, **OR**
- a history of severe adverse reactions to a **COVID-19** vaccine and/or component(s) of those vaccines, therefore vaccination with an available **COVID-19** vaccine is not recommended

Note:

EVUSHELD is not a substitute for vaccination in individuals for whom COVID-19 vaccination is recommended.

***Access:** Find EVUSHELD at a Virginia location near you using the VDH COVID-19 Treatment Locator https://www.vdh.virginia.gov/mabs/covid-19-treatment-locator/*

Preparation and Storage:

Unopened vials must be kept refrigerated at 2°C to 8°C (36°F to 46°F). Discard the unused portion of the vials. If immediate administration is not possible, and the prepared syringes may be kept at room temperature (up to 25°C (77°F), **for a total time not to exceed 4 hours from vial puncture to administration.**

Carton (2 vials per pack)	**Components**	
	1 vial of Tixagevimab 300 mg/3.0 mL (100 mg/mL) **(dark grey cap)**	**1 vial of Cilgavimab** 300 mg/3.0 mL (100 mg/mL) **(white cap)**
NDC 0310-7442-02	**NDC 0310-8895-01**	**NDC 0310-1061-01**

**Patients who received the previously recommended dosage of 150 mg of tixagevimab and 150 mg of cilgavimab should receive an additional dosage of 150 mg of tixagevimab and 150 mg of cilgavimab as soon as possible.*

To access the most recent EVUSHELD Fact Sheets, please scan the QR code provided below.

http://www.evusheld.com

Updated March 2022

VDH VIRGINIA DEPARTMENT OF HEALTH